Construction and immunological study of recombinant hBD-2/PSMA chimeric protein eukaryotic expressive plasmid / 生物医学工程学杂志
Journal of Biomedical Engineering
;
(6): 283-287, 2005.
Article
in Chinese
| WPRIM
| ID: wpr-327081
ABSTRACT
The recombinant PSMA DNA vaccine for active immunotherapy of prostate cancer was investigated. Two DNA vaccine recombinant plasmids, pcDNA3.1/PSMA and pcDNA3.1/hBD-2-PSMA, were constructed by inserting the hBD-2 gene and PSMA gene into an eukarytoic expression vector pcDNA3.1. Expression of the two recombinants was detected in transfected COS-7 cells and inoculated mouse muscular cells by RT-PCR and immunohistochemical method. When immunized with pcDNA3.1/PSMA and pcDNA3.1/hBD-2-PSMA, the immunized BALB/c mice acquired specific antibody and T cell response to PSMA. The quantity of the spleen lymphocytes and their CTL activity against PSMA gene transfected-BALB/3T3 cells significantly increased in the immunized mice, and the CTL activity of lymphocytes from pcDNA3.1/hBD-2-PSMA immunized mice was significantly higher than that of pcDNA3.1/PSMA immunized mice. This result suggests that pcDNA3.1/hBD-2-PSMA would probably be developed as a DNA vaccine for the immunotherapy of prostate cancer.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pathology
/
Plasmids
/
Prostatic Neoplasms
/
Therapeutics
/
Recombinant Fusion Proteins
/
Tumor Cells, Cultured
/
Transfection
/
T-Lymphocytes, Cytotoxic
/
Immunotherapy, Active
/
3T3 Cells
Limits:
Animals
/
Humans
/
Male
Language:
Chinese
Journal:
Journal of Biomedical Engineering
Year:
2005
Type:
Article
Similar
MEDLINE
...
LILACS
LIS